|PHA Serum products|
32604223 2020. Therapeutic Potential of B-1a Cells in COVID-19.
32292627 ä. Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment
32265310 ä. Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19
32329380 2020. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)-induced pneumonia
32296777 2020. Mesenchymal stem cells and management of COVID-19 pneumonia
32214286 2020. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use
32366290 2020. Mesenchymal stem cells as a potential therapy for COVID-19
32373992 2020. MSCs transplantation may be a potential therapeutic strategy for COVID-19 treatment
32281052 ä. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future
32320535 2020. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019
32371362 2020. Mesenchymal stem cell (MSc) secretome: A possible therapeutic strategy for intensive-care COVID-19 patients
32257554 2020. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia
32257537 2020. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
32283815 2020. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use
32292113 2020. Stem Cell?Based Therapy for Coronavirus Disease 2019
32387262 ä. Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment
C7163352 ä. Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential
32472653 2020. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome.
32399655 2020. Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.
32489694 2020. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?
32489692 2020. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease.
32425691 2020. ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19.
32422152 2020. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.
32425638 2020. Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.
32479246 2020. Mesenchymal Stem Cell-based Therapy for COVID-19: Possibility and Potential.
32380908 2020. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19.
32423449 2020. Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients.
32520641 2020. Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.
32520639 2020. Response to Kim et al. re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19".
32425307 2020. Mesenchymal Stem Cells -Bridge Catalyst Between Innte And Adaptive Immunity In Covid 19.
32519302 2020. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
32546764 2020. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis.
32460839 2020. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
32526079 2020. Current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19.
32588163 2020. Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19.
32582401 2020. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.
32554953 2020. Can mesenchymal stem cell therapy be the interim management of COVID-19?
32420049 2020. Combating COVID-19 with Mesenchymal Stem Cell therapy.
|32606347 2020. Distinct stem/progenitor cells proliferate to regenerate the trachea, intrapulmonary airways and alveoli in COVID-19 patients.|
32574317 2020. Can Stem Cells Beat COVID-19: Advancing Stem Cells and Extracellular Vesicles Toward Mainstream Medicine for Lung Injuries Associated With SARS-CoV-2 Infections.
32562911 2020. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
32574263 2020. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
|32590321 2020. Endothelial progenitor cells and mesenchymal stem cells to overcome vascular deterioration and cytokine storm in critical patients with COVID-19.|
32595362 2020. Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection.
32570174 2020. SARS-CoV-2 infection and stem cells: Interaction and intervention.
32592163 2020. 'Primed' Mesenchymal Stem Cells: a Potential Novel Therapeutic for COVID19 Patients.
32564256 2020. Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises.